[Federal Register: November 1, 2005 (Volume 70, Number 210)]
[Notices]
[Page 65901-65902]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr01no05-57]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of Organization, Functions, and Delegations of Authority of
the Department of Health and Human Services (45 FR 67772-76, dated
October 14, 1980, and corrected at 45 FR 69296, October 30, 1980, as
amended most recently at 69 FR 77756, dated December 28, 2004) is
amended to reorganize the National Center for HIV, STD, & TB
Prevention.
Section C-B, Organization and Functions, is hereby amended as
follows:
Delete in its entirety the following titles and functional
statements: Division of AIDS, STD & TB Laboratory Research (CK7),
Office of the Director (CK71), HIV, Immunology and Diagnostics Branch
(CK72), HIV Immunology and Diagnostics Branch (CK73), Sexually
Transmitted Infectious Diseases Branch (CK74), Tuberculosis/
Mycobacteriology Branch (CK75).
Following the Training and Health Communication Branch (CK37),
Division of STD Prevention (CK3), insert the following:
Laboratory Reference and Research Branch, (CK38). (1) Performs
research on the pathogenesis, genetics, and immunology of syphilis and
other treponematoses, gonococcal and chlamydial infections, chancroid,
genital herpes, donovanosis, bacterial vaginosis and trichomoniasis;
(2) conducts and participates in clinical, field, and laboratory
research to develop, evaluate, and improve laboratory methods used in
the diagnosis and epidemiology of these sexually transmitted infections
(STIs); (3) provides consultation and reference/diagnostic services for
these STIs; (4) conducts laboratory-based surveillance for and research
on the genetics of antimicrobial resistance in Neisseria gonorrhoeae;
(5) serves as the WHO International Collaborating Center for Reference
and Research in Syphilis Serology; and (6) provides consultation and
laboratory support for international activities.
Following the International Research and Programs Branch (CK47),
Division of Tuberculosis Elimination (CK4), insert the following:
Mycobacteriology Branch (HCK48). (1) Provides laboratory support
for epidemic investigations, surveillance activities, and special
studies of tuberculosis and other mycobacteria-caused diseases; (2)
administers contracts to provide Mycobacterium tuberculosis genotyping,
maintains a national database of genotypes, and conducts operational
research to implement genotyping; (3) develops and evaluates new
methods to subtype mycobacteria for epidemiologic studies; (4) serves
as primary CDC focus for diagnostic mycobacteriology laboratory
services and for laboratory aspects of nontuberculosis Mycobacterium
species and of Hansen disease (leprosy); (5) administers grants and
cooperative agreements with states and others to upgrade laboratory
activities and provide special services; (6) provides reference
diagnostic services, consultation, technical assistance, and training
to State, Federal, and municipal public health laboratories; (7)
provides laboratory support, reference services, assessment,
consultation, and training for CDC's international tuberculosis
activities; (8) develops, evaluates, or improves conventional and
molecular methods for the detection, classification, identification,
characterization, and susceptibility testing of mycobacteria and
mycobacteria-caused diseases; (9) conducts studies to define the role
of bacterial virulence factors, host factors, and pathogenic and
immunologic mechanisms in disease processes and protective immunity and
develops, evaluates, and improves immunologic methods for the diagnosis
and prevention of mycobacteria-caused diseases; (10) develops tissue
culture and animal models of mycobacteria-caused diseases and conducts
studies on chemotherapy, immunotherapy, pathogenesis, pathology, and
vaccines for mycobacteria-caused diseases; (11) conducts studies on the
isolation, taxonomy, and ecology of mycobacteria and develops tests to
identify new species; (12) conducts and supports studies to
characterize newly emerging pathogenic species of Mycobacterium and
associated diseases.
Following the HIV Incidence and Case Surveillance Branch (CK56),
Division of HIV, AIDS Prevention--Surveillance and Epidemiology (CK5),
insert the following:
HIV and Retrovirology Laboratory Branch (HCK57). (1) Conducts
studies of human immunodeficiency viruses (HIVs) and other human and
zoonotic retroviruses, including the diseases they cause, their modes
of transmission, and the means for their control through virus
detection, isolation, and characterization by virologic, molecular, and
cellular biologic methods; (2)
[[Page 65902]]
collaborates with NCHSTP investigators to conduct HIV epidemiologic and
surveillance studies worldwide particularly as they pertain to
prevention and intervention strategies; (3) identifies and
characterizes new HIV isolates and develops new screening tests for
these isolates to determine their prevalence in various populations;
(4) determines geotypic and phenotypic variations of HIVs that may
affect pathogenesis, drug resistance, persistence, virulence, and
transmissibility; (5) conducts and supports field epidemiologic
investigations of the prevalence, distribution, trends, and risk
factors associated with non-AIDS retroviral infections and associated
diseases; (6) serves as a World Health Organization (WHO) Reference
Center and as a member of the UNAIDS Virus Network to provide
international consultation and technical assistance on laboratory
procedures for HIV isolation, detection, and characterization; (7)
develops and evaluates procedures for the isolation and
characterization of HIV and for the detection of retroviral DNA or RNA
from clinical samples; (8) provides training, reference testing, and
reference reagents for virologic and molecular characterization of
divergent HIVs for public health laboratories in the United States and
WHO; (9) serves as a reference laboratory for the isolation of zoonotic
retroviruses from clinical samples; (10) develops collaborations with
other CDC and non-CDC scientists to promote scientific progress and
accomplishments; and (11) collaborates with industry to promote
commercialization of useful technology, methodologies, and reagents of
public health importance.
HIV Immunology and Diagnostic Laboratory Branch (HCK58). (1)
Conducts basic and applied studies of microbial-host interactions that
occur in infections, particularly infection with human immunodeficiency
virus (HIV); (2) conducts basic and applied investigations of the
immune cell interactions that occur in HIV infection as well as in
related immunologic/infectious diseases; conducts investigations of
genetic traits of the host that influence the susceptibility, disease
course, and immune response to infectious disease, particularly HIV
diseases; (3) conducts studies related to the development, evaluation,
improvement, and standardization of laboratory technologies uses for
the diagnosis, surveillance, and monitoring of HIV infection both
independently and in collaboration with the biotechnology industry; (4)
performs HIV antigen and antibody testing plus related standardized
assays in support of the diagnostic/surveillance/epidemiologic
requirements of CDC-based and CDC-affiliated studies of the HIV
epidemic; (5) serves as a reference laboratory for State and local
health departments; and (6) provides diagnostic services to other
Federal agencies, the World Health Organization, CDC-affiliated
academic centers, CDC-affiliated studies with other countries, and
community organizations, as appropriate.
Dated: April 1, 2005.
William H. Gimson,
Chief Operating Officer, Centers for Disease Control and Prevention
(CDC).
[FR Doc. 05-21672 Filed 10-31-05; 8:45 am]
BILLING CODE 4160-18-M